52 results
Keyword Jevtana Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Jevtana
cabazitaxel, Prostatic Neoplasms
Date of authorisation: 17/03/2011, Revision: 19, Authorised, Last updated: 15/04/2021Jevtana Prostatic Neoplasms … Jevtana … Jevtana, INN-cabazitaxel 30 … -
List item
Direct healthcare professional communication (DHPC): Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: Risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Active substance: cabazitaxel, DHPC type: Medication error, Last updated: 28/10/2020medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate … medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate … -
List item
Human medicine European public assessment report (EPAR): Cabazitaxel Accord
cabazitaxel, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 28/08/2020,
, 
, Authorised, Last updated: 28/10/2020
for Cabazitaxel Accord is Jevtana. Expand section Collapse section … with the reference medicine, Jevtana, and do not need to be repeated … and to be bioequivalent to Jevtana. Therefore, the Agency’s … -
List item
Human medicine European public assessment report (EPAR): Cabazitaxel Teva
cabazitaxel, Prostatic Neoplasms
Date of refusal: 11/07/2019, Refused, Last updated: 24/07/2019reference to two medicines, Jevtana (containing cabazitaxel … as the reference medicine, Jevtana. Cabazitaxel belongs to the … demonstrate that it is similar to Jevtana. There was no need for ‘bioequivalence’ … -
List item
National expert: Pierre Demolis, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 21.86 KB | PDF
-
List item
National expert: Hugues Malonne, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 81.12 KB | PDF
- Curriculum Vitae - 34.11 KB | PDF
09/2016-12/2016 Sanofi Omnivit - Jevtana - Praluent multivitamins … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 January 2011
CHMP, Last updated: 21/01/2011Jevtana … review time of 180 days. • Jevtana (cabazitaxel), from Sanofi-aventis … docetaxel-containing regimen. The review for Jevtana began on 26 May 2010 with … -
List item
Parallel distribution: Regulatory and procedural guidance (updated)
Last updated: 09/06/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2020
European Medicines Agency, Amsterdam, the Netherlands, from 06/07/2020 to 09/07/2020, Last updated: 10/12/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2020
Virtual meeting, from 12/10/2020 to 15/10/2020, Last updated: 16/10/2020 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 07/06/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 04/03/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 January 2014
European Medicines Agency, London, UK, from 06/01/2014 to 09/01/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 July 2013
European Medicines Agency, London, UK, from 08/07/2013 to 11/07/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 December 2013
European Medicines Agency, London, UK, from 02/12/2013 to 05/12/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 October 2013
European Medicines Agency, London, UK, from 07/10/2013 to 10/10/2013, Last updated: 02/07/2012of the PRAC Minutes) * Jevtana - correction on page 18 7 … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 January 2013
European Medicines Agency, London, UK, from 07/01/2013 to 10/01/2013, Last updated: 02/06/2012 -
List item
PRAC: meeting archive 2012-2013
Last updated: 13/05/2016 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 January 2016
European Medicines Agency, London, UK, from 11/01/2016 to 14/01/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 July 2014
European Medicines Agency, London, UK, from 07/07/2014 to 10/07/2014, Last updated: 13/08/2013 -
List item
Download medicine data
Last updated: 29/04/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 January 2011
European Medicines Agency, London, UK, from 17/01/2011 to 20/01/2011, Last updated: 11/06/2010review time of 180 days. • Jevtana (cabazitaxel), from Sanofi-aventis … docetaxel-containing regimen. The review for Jevtana began on 26 May 2010 with … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 January 2015
European Medicines Agency, London, UK, from 06/01/2015 to 09/01/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 January 2017
European Medicines Agency, London, UK, from 09/01/2017 to 12/01/2017, Last updated: 13/03/2014